140 related articles for article (PubMed ID: 37195701)
1. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy.
Lampert R; Ackerman MJ; Marino BS; Burg M; Ainsworth B; Salberg L; Tome Esteban MT; Ho CY; Abraham R; Balaji S; Barth C; Berul CI; Bos M; Cannom D; Choudhury L; Concannon M; Cooper R; Czosek RJ; Dubin AM; Dziura J; Eidem B; Emery MS; Estes NAM; Etheridge SP; Geske JB; Gray B; Hall K; Harmon KG; James CA; Lal AK; Law IH; Li F; Link MS; McKenna WJ; Molossi S; Olshansky B; Ommen SR; Saarel EV; Saberi S; Simone L; Tomaselli G; Ware JS; Zipes DP; Day SM;
JAMA Cardiol; 2023 Jun; 8(6):595-605. PubMed ID: 37195701
[TBL] [Abstract][Full Text] [Related]
2. Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy.
Fumagalli C; Maurizi N; Day SM; Ashley EA; Michels M; Colan SD; Jacoby D; Marchionni N; Vincent-Tompkins J; Ho CY; Olivotto I;
JAMA Cardiol; 2020 Jan; 5(1):65-72. PubMed ID: 31693057
[TBL] [Abstract][Full Text] [Related]
3. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy.
Eberly LA; Day SM; Ashley EA; Jacoby DL; Jefferies JL; Colan SD; Rossano JW; Semsarian C; Pereira AC; Olivotto I; Ingles J; Seidman CE; Channaoui N; Cirino AL; Han L; Ho CY; Lakdawala NK
JAMA Cardiol; 2020 Jan; 5(1):83-91. PubMed ID: 31799990
[TBL] [Abstract][Full Text] [Related]
4. Vigorous exercise in patients with hypertrophic cardiomyopathy.
Dejgaard LA; Haland TF; Lie OH; Ribe M; Bjune T; Leren IS; Berge KE; Edvardsen T; Haugaa KH
Int J Cardiol; 2018 Jan; 250():157-163. PubMed ID: 29169752
[TBL] [Abstract][Full Text] [Related]
5. The Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy.
Conway J; Min S; Villa C; Weintraub RG; Nakano S; Godown J; Tatangelo M; Armstrong K; Richmond M; Kaufman B; Lal AK; Balaji S; Power A; Baez Hernandez N; Gardin L; Kantor PF; Parent JJ; Aziz PF; Jefferies JL; Dragulescu A; Jeewa A; Benson L; Russell MW; Whitehill R; Rossano J; Howard T; Mital S
Circulation; 2023 Feb; 147(9):718-727. PubMed ID: 36335467
[TBL] [Abstract][Full Text] [Related]
6. Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events.
Maurizi N; Passantino S; Spaziani G; Girolami F; Arretini A; Targetti M; Pollini I; Tomberli A; Pradella S; Calabri GB; Vinattieri V; Bertaccini B; Leone O; De Simone L; Rapezzi C; Marchionni N; Cecchi F; Favilli S; Olivotto I
JAMA Cardiol; 2018 Jun; 3(6):520-525. PubMed ID: 29710196
[TBL] [Abstract][Full Text] [Related]
7. Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario.
Weissler-Snir A; Allan K; Cunningham K; Connelly KA; Lee DS; Spears DA; Rakowski H; Dorian P
Circulation; 2019 Nov; 140(21):1706-1716. PubMed ID: 31630535
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study.
Balaji S; DiLorenzo MP; Fish FA; Etheridge SP; Aziz PF; Russell MW; Tisma S; Pflaumer A; Sreeram N; Kubus P; Law IH; Kantoch MJ; Kertesz NJ; Strieper M; Erickson CC; Moore JP; Nakano SJ; Singh HR; Chang P; Cohen M; Fournier A; Ilina MV; Smith RT; Zimmerman F; Horndasch M; Li W; Batra A; Liberman L; Hamilton R; Janson CM; Sanatani S; Zeltser I; McDaniel G; Blaufox AD; Garnreiter JM; Katcoff H; Shah M
Heart Rhythm; 2019 Oct; 16(10):1462-1467. PubMed ID: 31026510
[TBL] [Abstract][Full Text] [Related]
9. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
10. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.
Rowin EJ; Maron BJ; Haas TS; Garberich RF; Wang W; Link MS; Maron MS
J Am Coll Cardiol; 2017 Feb; 69(7):761-773. PubMed ID: 28209216
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
[TBL] [Abstract][Full Text] [Related]
12. High-Sensitivity Cardiac Troponin T Elevation in Hypertrophic Cardiomyopathy Is Associated With Ventricular Arrhythmias.
Burczak DR; Newman DB; Jaffe AS; Ackerman MJ; Ommen SR; Geske JB
Mayo Clin Proc; 2023 Mar; 98(3):410-418. PubMed ID: 36868748
[TBL] [Abstract][Full Text] [Related]
13. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study.
Pelliccia A; Caselli S; Pelliccia M; Musumeci MB; Lemme E; Di Paolo FM; Maestrini V; Russo D; Limite L; Borrazzo C; Autore C
Br J Sports Med; 2020 Aug; 54(16):1008-1012. PubMed ID: 32532845
[TBL] [Abstract][Full Text] [Related]
16. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
[TBL] [Abstract][Full Text] [Related]
17. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
Elliott PM; Sharma S; Varnava A; Poloniecki J; Rowland E; McKenna WJ
J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
[TBL] [Abstract][Full Text] [Related]
18. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
19. Automated Quantification of Abnormal QRS Peaks From High-Resolution ECGs Predicts Late Ventricular Arrhythmias in Hypertrophic Cardiomyopathy: A 5-Year Prospective Multicenter Study.
Suszko AM; Chakraborty P; Viswanathan K; Barichello S; Sapp J; Talajic M; Laksman Z; Yee R; Woo A; Spears D; Adler A; Rakowski H; Chauhan VS
J Am Heart Assoc; 2022 Dec; 11(23):e026025. PubMed ID: 36444865
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Begley DA; Mohiddin SA; Tripodi D; Winkler JB; Fananapazir L
Pacing Clin Electrophysiol; 2003 Sep; 26(9):1887-96. PubMed ID: 12930505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
